Central Nervous System Lymphoma

hematologic malignancy

Identifier: CI-CAN-00000653
Entity page: /cancer/central-nervous-system-lymphoma ↗
Edges: 277

Neighbours: 4 genes15 drugs10 trials
Drawn: 29 of 29 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Central Nervous System Lymphoma approved for …APPROVED_FORderived1 of 1
← approved for	Cytarabinesmall molecule EMA (EU) · withdrawn · 2001-07-11 · Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the …	—	withdrawn	Meningeal Lymphoma	1	Regulatory	ema	graph →
Central Nervous System Lymphoma …

Central Nervous System Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 58show all (up to 200)
→ investigated in trials for	Methotrexatesmall molecule 34 trials (14 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 34 trials (15 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 15 trials (6 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 13 trials (6 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Zanubrutinibsmall molecule 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Acalabrutinibsmall molecule 4 trials (4 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Obinutuzumabmonoclonal antibody 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 4 trials (2 active) · roll-up of the cancer and its descendants	—	—	Central Nervous System Lymphoma	4	Observed	clinicaltrials	graph →

Central Nervous System Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 58show all (up to 200)

→ investigated in trials for

Methotrexatesmall molecule

34 trials (14 active) · roll-up of the cancer and its descendants

—

Central Nervous System Lymphoma

Observed

Central Nervous System Lymphoma studied in …STUDIED_INderived10 of 214show all (up to 200)
→ studied in	NCT07839247Phase 2 · recruiting Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07842835not yet recruiting Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China (CLIMB) · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06175000Phase 2 · recruiting Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04688151Phase 1 · completed Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04462328Phase 1 · active not recruiting Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03964090Phase 2 · active not recruiting Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04609046Phase 1 · active not recruiting Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System	1	Observed	clinicaltrials	graph →
→ studied in	NCT02203526Phase 1 · active not recruiting Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 214 trials mapped (90 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07608731Phase 1 · not yet recruiting Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas · condition mapped ONTOLOGY_EXACT · 214 trials mapped (90 active)	—	—	Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains